[go: up one dir, main page]

Di Gregorio, 2021 - Google Patents

Protein misfolding toxicity and inclusion formation in cellular models of neurodegeneration

Di Gregorio, 2021

View PDF
Document ID
7009526190775950030
Author
Di Gregorio S
Publication year

External Links

Snippet

Protein misfolding characterizes most neurodegenerative diseases. Protein misfolding is the conversion of specific proteins from their normal, often soluble, and native three-dimensional conformation into an aberrant, often insoluble, non-functional conformation. Protein …
Continue reading at ir.lib.uwo.ca (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Similar Documents

Publication Publication Date Title
Wolozin et al. Stress granules and neurodegeneration
Labbadia et al. The biology of proteostasis in aging and disease
Meier et al. Pathological tau promotes neuronal damage by impairing ribosomal function and decreasing protein synthesis
Lee et al. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration
US20180119141A1 (en) Crispr/cas global regulator screening platform
Klaips et al. Sis1 potentiates the stress response to protein aggregation and elevated temperature
Fernandes et al. Stress granules and ALS: a case of causation or correlation?
Butler et al. Tau/MAPT disease-associated variant A152T alters tau function and toxicity via impaired retrograde axonal transport
US8865411B2 (en) Methods of identifying modulators of TDP-43 mediated cellular toxicity
US20060223812A1 (en) Treating neurodegenerative conditions
Lin et al. Overexpression of heat shock factor 1 maintains TAR DNA binding protein 43 solubility via induction of inducible heat shock protein 70 in cultured cells
Cook et al. TDP-43 in neurodegenerative disorders
US11896678B2 (en) Compositions and methods for treatment of peroxisome proliferator-activated receptor gamma (PPARG) activated cancer
Torres et al. Proteostasis deregulation as a driver of C9ORF72 pathogenesis
Di Gregorio Protein misfolding toxicity and inclusion formation in cellular models of neurodegeneration
US20250215059A1 (en) Methods and compositions for disrupting tau aggregates using polyserine repeat sequences targeting exogenous proteins
Badiola et al. Tau phosphorylation and aggregation as a therapeutic target in tauopathies
US20240050440A1 (en) Therapeutic targets and agents for the treatment of triosephosphate isomerase (tpi) deficiency
US20200268855A1 (en) Use of aldh1a and agonist, catalyst and inhibitor thereof
Herod The contribution of 14-3-3 proteins to protein aggregate homeostasis
Wahhab Investigating the Role of Dysregulated Protein Translation in the Pathogenesis of X-linked Myotubular Myopathy
Fun Adaptor protein WDFY3 is neuroprotective by counteracting age-dependent decline in proteostasis
SALINEE The roles of Drosophila ubiquilin in neurological disorders
Alspaugh Investigating the Mechanism of TDP-43 Toxicity in Yeast: a Model for Amyotrophic Lateral Sclerosis
Tedesco GAIN OF TOXIC FUNCTION OF CHAPERONE ASSISTED SELECTIVE AUTOPHAGY MEMBERS IN NEUROMUSCULAR DISEASES: A CHARACTERIZATION OF DISEASE-RELATED MUTANTS